Literature DB >> 24862638

Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies.

Mary Eapen1, Paul O'Donnell2, Claudio G Brunstein3, Juan Wu4, Kate Barowski4, Adam Mendizabal4, Ephraim J Fuchs5.   

Abstract

Two parallel phase II trials in adults with hematologic malignancies demonstrated comparable survival after reduced-intensity conditioning and transplantation of either 2 HLA-mismatched umbilical cord blood (UCB) units or bone marrow from HLA-haploidentical relatives. Donor choice is often subject to physician practice and institutional preference. Despite clear preliminary evidence of equipoise between HLA-haploidentical related donor and double unrelated donor UCB transplantation, the actual prospect of being randomized between these 2 very different donor sources is daunting to patients and their treating physicians alike. Under these circumstances, it is challenging to conduct a phase III randomized trial in which patients are assigned to the UCB or haploidentical bone marrow arms. Therefore, we aimed to provide an evidence-based review and recommendations for selecting donors for adults without an HLA-matched sibling or an HLA-matched adult unrelated donor.
Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alternative donor transplantation; Donor selection algorithm; Hematologic malignancy

Mesh:

Substances:

Year:  2014        PMID: 24862638      PMCID: PMC4163123          DOI: 10.1016/j.bbmt.2014.05.015

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  45 in total

1.  Cord-blood engraftment with ex vivo mesenchymal-cell coculture.

Authors:  Marcos de Lima; Ian McNiece; Simon N Robinson; Mark Munsell; Mary Eapen; Mary Horowitz; Amin Alousi; Rima Saliba; John D McMannis; Indreshpal Kaur; Partow Kebriaei; Simrit Parmar; Uday Popat; Chitra Hosing; Richard Champlin; Catherine Bollard; Jeffrey J Molldrem; Roy B Jones; Yago Nieto; Borje S Andersson; Nina Shah; Betul Oran; Laurence J N Cooper; Laura Worth; Muzaffar H Qazilbash; Martin Korbling; Gabriela Rondon; Stefan Ciurea; Doyle Bosque; Ila Maewal; Paul J Simmons; Elizabeth J Shpall
Journal:  N Engl J Med       Date:  2012-12-13       Impact factor: 91.245

2.  Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies.

Authors:  Paolo Di Bartolomeo; Stella Santarone; Gottardo De Angelis; Alessandra Picardi; Laura Cudillo; Raffaella Cerretti; Gaspare Adorno; Stefano Angelini; Marco Andreani; Lidia De Felice; Maria Cristina Rapanotti; Loredana Sarmati; Pasqua Bavaro; Gabriele Papalinetti; Marta Di Nicola; Franco Papola; Mauro Montanari; Arnon Nagler; William Arcese
Journal:  Blood       Date:  2012-11-19       Impact factor: 22.113

3.  The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors.

Authors:  Yasuo Morishima; Takehiko Sasazuki; Hidetoshi Inoko; Takeo Juji; Tatsuya Akaza; Ken Yamamoto; Yoshihide Ishikawa; Shunichi Kato; Hiroshi Sao; Hisashi Sakamaki; Keisei Kawa; Nobuyuki Hamajima; Shigetaka Asano; Yoshihisa Kodera
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

Review 4.  Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provision.

Authors:  R N Lown; B E Shaw
Journal:  Bone Marrow Transplant       Date:  2012-04-09       Impact factor: 5.483

5.  Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000).

Authors:  Yoshinobu Kanda; Shigeru Chiba; Hisamaru Hirai; Hisashi Sakamaki; Tohru Iseki; Yoshihisa Kodera; Takahiro Karasuno; Shinichiro Okamoto; Noriyuki Hirabayashi; Koji Iwato; Atsuo Maruta; Yoshihiro Fujimori; Tatsuo Furukawa; Shin Mineishi; Keitaro Matsuo; Nobuyuki Hamajima; Masahiro Imamura
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

6.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

7.  Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia.

Authors:  Andromachi Scaradavou; Claudio G Brunstein; Mary Eapen; Jennifer Le-Rademacher; Juliet N Barker; Nelson Chao; Corey Cutler; Colleen Delaney; Fangyu Kan; Luis Isola; Chatchada Karanes; Mary J Laughlin; John E Wagner; Elizabeth J Shpall
Journal:  Blood       Date:  2012-12-09       Impact factor: 22.113

8.  Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization.

Authors:  J Pidala; J Kim; M Schell; S J Lee; R Hillgruber; V Nye; E Ayala; M Alsina; B Betts; R Bookout; H F Fernandez; T Field; F L Locke; T Nishihori; J L Ochoa; L Perez; J Perkins; J Shapiro; C Tate; M Tomblyn; C Anasetti
Journal:  Bone Marrow Transplant       Date:  2012-08-06       Impact factor: 5.483

9.  Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.

Authors:  Anna Maria Raiola; Alida Dominietto; Anna Ghiso; Carmen Di Grazia; Teresa Lamparelli; Francesca Gualandi; Stefania Bregante; Maria Teresa Van Lint; Simona Geroldi; Silvia Luchetti; Filippo Ballerini; Maurizio Miglino; Riccardo Varaldo; Andrea Bacigalupo
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-29       Impact factor: 5.742

10.  The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.

Authors:  A Bishara; D De Santis; C C Witt; C Brautbar; F T Christiansen; R Or; A Nagler; S Slavin
Journal:  Tissue Antigens       Date:  2004-03
View more
  16 in total

1.  Engineering haploidentical transplants.

Authors:  S Naik; H E Heslop
Journal:  Bone Marrow Transplant       Date:  2015-05-11       Impact factor: 5.483

2.  Hematopoietic cell transplantation for acute leukemia: selecting donors.

Authors:  Mary Eapen
Journal:  Haematologica       Date:  2015-04       Impact factor: 9.941

Review 3.  The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation.

Authors: 
Journal:  Biol Blood Marrow Transplant       Date:  2016-07-11       Impact factor: 5.742

4.  Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101).

Authors:  Ephraim J Fuchs; Paul V O'Donnell; Mary Eapen; Brent R Logan; Joseph H Antin; Peter Dawson; Steven M Devine; Mary M Horowitz; Mitchell E Horwitz; Chatchada Karanes; Eric Leifer; John M Magenau; Joseph Patrick McGuirk; Lawrence E Morris; Andrew R Rezvani; Richard J Jones; Claudio G Brunstein
Journal:  Blood       Date:  2020-08-31       Impact factor: 22.113

5.  Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.

Authors:  J Schetelig; M Schaich; K Schäfer-Eckart; M Hänel; W E Aulitzky; H Einsele; N Schmitz; W Rösler; M Stelljes; C D Baldus; A D Ho; A Neubauer; H Serve; J Mayer; W E Berdel; B Mohr; U Oelschlägel; S Parmentier; C Röllig; M Kramer; U Platzbecker; T Illmer; C Thiede; M Bornhäuser; G Ehninger
Journal:  Leukemia       Date:  2014-12-01       Impact factor: 11.528

6.  Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

Authors:  Stefan O Ciurea; Mei-Jie Zhang; Andrea A Bacigalupo; Asad Bashey; Frederick R Appelbaum; Omar S Aljitawi; Philippe Armand; Joseph H Antin; Junfang Chen; Steven M Devine; Daniel H Fowler; Leo Luznik; Ryotaro Nakamura; Paul V O'Donnell; Miguel-Angel Perales; Sai Ravi Pingali; David L Porter; Marcie R Riches; Olle T H Ringdén; Vanderson Rocha; Ravi Vij; Daniel J Weisdorf; Richard E Champlin; Mary M Horowitz; Ephraim J Fuchs; Mary Eapen
Journal:  Blood       Date:  2015-06-30       Impact factor: 22.113

7.  Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.

Authors:  Bipin N Savani; Myriam Labopin; Nicolaus Kröger; Jürgen Finke; Gerhard Ehninger; Dietger Niederwieser; Rainer Schwerdtfeger; Donald Bunjes; Bertram Glass; Gerard Socié; Per Ljungman; Charles Craddock; Frédéric Baron; Fabio Ciceri; Norbert Claude Gorin; Jordi Esteve; Christoph Schmid; Sebastian Giebel; Mohamad Mohty; Arnon Nagler
Journal:  Haematologica       Date:  2016-03-11       Impact factor: 9.941

8.  Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis.

Authors:  P V O'Donnell; M Eapen; M M Horowitz; B R Logan; A DiGilio; C Brunstein; E J Fuchs; M E D Flowers; R Salit; K Raj; A Pagliuca; K Bradstock; A Granata; L Castagna; S Furst; D Blaise
Journal:  Bone Marrow Transplant       Date:  2016-08-15       Impact factor: 5.483

9.  Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation.

Authors:  Karen Ballen; Kwang Woo Ahn; Min Chen; Hisham Abdel-Azim; Ibrahim Ahmed; Mahmoud Aljurf; Joseph Antin; Ami S Bhatt; Michael Boeckh; George Chen; Christopher Dandoy; Biju George; Mary J Laughlin; Hillard M Lazarus; Margaret L MacMillan; David A Margolis; David I Marks; Maxim Norkin; Joseph Rosenthal; Ayman Saad; Bipin Savani; Harry C Schouten; Jan Storek; Paul Szabolcs; Celalettin Ustun; Michael R Verneris; Edmund K Waller; Daniel J Weisdorf; Kirsten M Williams; John R Wingard; Baldeep Wirk; Tom Wolfs; Jo-Anne H Young; Jeffrey Auletta; Krishna V Komanduri; Caroline Lindemans; Marcie L Riches
Journal:  Biol Blood Marrow Transplant       Date:  2016-06-22       Impact factor: 5.742

Review 10.  Modern approaches to HLA-haploidentical blood or marrow transplantation.

Authors:  Christopher G Kanakry; Ephraim J Fuchs; Leo Luznik
Journal:  Nat Rev Clin Oncol       Date:  2015-08-25       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.